There are eight types of Botulinum toxins(BTX) known(A-H) and A and B are used in commercially and medically. Type C-G are less common in human and cause disease in animals. Peptide toxin(PTx) is a small peptide that has shown enzymatic cleavage activity in Syntaxin and SNAP-25 which decreases acetylcholine release in nerve cell, in result. Clinical test of topical PTx has shown strong wrinkle improvement, down regulation of sebum and pore size, and soothing effect in skin redness. Into the bargain, all other evidences imply that PTx can be used in topical in pharmaceutical applications, like hyperhidrosis, acne, atopic dermatitis, chronic pain relief, etc.

Investment climate and opportunities

Uganda is enforcing effective macro-economic policies that maintained economic growth at an average of 6.5%. It is rich in natural resources, both human and minerals. Government provides a wide range of incentives, such as 100% foreign ownership of companies, in favour of the investors.

Cameroon (also referred to as the “Africa in miniature”) has Central Africa’s most diversified economy and in 2009, she launched the Document “de Stratégie pour la Croissance et l’Emploi (DSCE)”, with the goal of making the country an emerging economy by 2035. However, recently the business environment is quite challenging due to the security crises in the north and Anglophone regions and some corruption. Despite the downturn, the government in Yaoundé has big plans for the economy. With a pharmaceutical sector dominated by both the public sector and the private sector yet with uneasy access to even essential drugs, leading to growing threat from the illegal medicine market, this presents fertile opportunities for investors in the sector given the government’s willingness and determination to ensure universal health coverage (UHC) for the population.

According to the state program for the development of the pharmaceutical industry, the government’s priority task is to supply 50% of the market with locally produced medicines and healthcare products by 2018. To meet this goal, modernization of existing and construction of new pharmaceutical production facilities are planned.

Asia has become a critical mass that can drive innovation in life sciences. In this presentation, I will share my perspectives on a R&D ecosystem in Asia with general industry trends and strategy. As collaboration and alliance through “Open Innovation” became a key success scheme, the presentation will be focused on how we can leverage the system to ensure advances in emerging science. With a glimpse of future R&D, I will conclude my talk with idea how we, as drivers in science and technology, should prepare ourselves to drive transformation in life science to provide best care to patients.

의약품은 온도유지 및 스페셜 케어를 요구하는 중요한 산업 중 하나입니다. 브링스의 전문적인 콜드체인 운송 경험에 근거하여 의약품 안전을 위한 공급망 관리 방법에 대해 논의하고 케이스 스터디로 브링스 온도유지 차량 밸리데이션과 운송 프로세스에 대한 사례 검토가 공급망 안전 보완에 도움이 될 것입니다.

모리나가사는 인체내 점유율이 가장 높은 인체유래 비피더스균종(아기의 장유래, Bifidobacterium Longum, Breve, Infantis)을 연구하고 있으며, 인체유래 비피더스균으로(BB536, M-16V) 가장 많은임상을 수행하였습니다. 또한, 뛰어난 상온 안정성 (50% 이상 생존, 2년 37도, 수분활성 0.25) 가지고 있습니다.

모리시타진탄은 심리스캡슐을 반세기 이상 연구하며 독자 기술을 보유하고 있습니다.
심리스캡슐은 식품 (Flavor캡슐 및 장용성 프로바이오틱스 캡슐) 및 의약품 분야(내열, 내산, pH 의존붕괴, 서방성) 등 다양한 응용이 가능합니다.

Please join us to learn about Aquae Care’s novel dietary supplement and capitalize on the growing natural health market. We would like to introduce you to the microalgae Aphanizomenon flos-aquae known as Wild AFA ® and discuss the broad spectrum nutritional value, wide-ranging health benefits, and applications of this superfood.

Increasingly, Isolators designed for aseptic processing activities such as vial and syringe filling lines are being required to meet stringent OEB/OEL levels based on the potency of the product. This presents a number of challenges regarding the traditional design approach such as operating pressure, operator safety, filtration requirements and cleanability. Here we discuss those challenges and explore what alternatives in design could be adopted to meet the design requirements but not put either the product or operator at risk.

The seminar will discuss the challenges faced by the Pharmaceutical Industry in API Manufacturing and Formulation development and how leveraging computational Technologies such as CFD and DEM can help reduce the time to market and improve overall process performance. The seminar will present a few case studies highlighting the impact of these studies on overall productivity and profitability.